The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...

The U.S. Food and Drug Administration (FDA) is changing the game on COVID-19 vaccines. Instead of approving yearly boosters ...

Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...

After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...

The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.

The FDA also requested Novavax conduct a phase 4 study in patients aged 50 to 64 years without high-risk conditions for severe COVID-19.

19日の米株式市場で米バイオテクノロジー企業ノババックスの株価が急伸した。米規制当局が同社の新型コロナウイルスワクチンを完全に承認したことで、承認遅延や有効性を疑問視するケネディ厚生長官の発言により高まっていた市場の不安が和らいだ。

Covid shots are facing greater scrutiny from top federal health officials like RFK Jr. and the FDA's Marty Makary.

The approval of Nuvaxovid for use in older and high-risk adults will generate around $175 million in milestone payments from ...